Last reviewed · How we verify
TAK-385 Tablets
At a glance
| Generic name | TAK-385 Tablets |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) (PHASE2)
- The University of Miami Adapt (UAdapt) Trial (PHASE2)
- Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer (PHASE1)
- Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy (PHASE3)
- Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL) (PHASE4)
- The COSMYC Trial (COmbined Suppression of MYC) (PHASE2)
- Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-385 Tablets CI brief — competitive landscape report
- TAK-385 Tablets updates RSS · CI watch RSS
- Takeda portfolio CI